Congress Scientific Watch

From ESMO Breast Cancer 2022:
For patients with hormone receptor-positive, HER2-negative advanced breast cancer, the addition of ribociclib to fulvestrant continues to significantly improves overall survival after more than 70 months

From ESMO Breast Cancer 2022:
Preliminary phase Ib/II trial results suggest that first-line treatment with datopotamab deruxtecan plus durvalumab is active against locally advanced and metastatic triple-negative breast cancer

From ESMO Breast Cancer 2022:
Trastuzumab deruxtecan may help control intracranial metastases in patients with HER2-positive breast cancer

From ESMO Breast Cancer 2022:
Patients recruited to the monarchE trial on the basis of a high clinicopathological risk of early breast cancer recurrence derive a significant invasive disease-free survival benefit from abemaciclib use

From ESMO Breast Cancer 2022:
A single dose of HER3-targeted antibody–drug conjugate induces a CelTIL response in treatment-naïve early-stage hormone receptor-positive, HER2-negative breast cancer

From the 2022 AACR Annual Meeting:
A bispecific antibody targeting PD-1 and CTLA-4 has shown peripheral T-cell proliferation and anti-tumour activity in a range of advanced cancers

From the 2022 AACR Annual Meeting:
Combining neoadjuvant durvalumab with oleclumab, monalizumab or danvatirsen may offer novel strategies for early-stage NSCLC

From the 2022 AACR Annual Meeting:
Olaparib given with metronomic cyclophosphamide and metformin may have activity against recurrent, advanced endometrial cancer

From the 2022 AACR Annual Meeting:
People with solid tumours, particularly testicular cancer, could benefit from claudin-6 targeted CAR-T cell therapy alone or in combination with a vaccine designed to boost CAR-T cell persistence

From the 2022 AACR Annual Meeting:
First-in-human data suggest that the novel bicyclic peptide BT8009 warrants further study in people with Nectin-4 expressing advanced solid tumours

From the European Lung Cancer Congress 2022
Tumour mutational burden may be predicted by presence of mutations in both homologous recombination repair and mismatch repair genes in people with lung cancer

From the European Lung Cancer Congress 2022
Patients with stage II–IIIB N2 NSCLC and a relevant EGFR mutation may benefit from neoadjuvant osimertinib